Received for publication February 1, 2007.
Revised March 23, 2007.
Accepted for publication March 27, 2007.

RISK ASSESSMENT FOR DRUG-DRUG INTERACTION CAUSED BY METABOLISM-BASED INHIBITION OF CYP3A USING AUTOMATED IN VITRO ASSAY SYSTEMS AND ITS APPLICATION IN THE EARLY DRUG DISCOVERY PROCESS

Abstract

CYP3A family is a major drug metabolism enzyme in humans. Metabolism-based inhibition of CYP3A might cause clinically significant drug-drug interactions. To assess the risk of DDI caused by MBI of CYP3A, we established an automated single time- and concentration-dependent inhibition assay. To create a diagram to assess DDI risk of compounds in the early discovery stage, we classified 171 marketed drugs by the possibility of the occurence of in vivo DDI caused by MBI from the relationship between the inactivation activity determined in the MBI screening, the therapeutic blood or plasma concentration, and the in vivo DDI information. This analysis revealed that the DDI risk depends on both the MBI potential and blood concentration of a compound, and provided the criteria of the DDI risk. In the assay, 3 compounds (midazolam, nifedipine, and testosterone) were compared as CYP3A probe substrates. The results show that the evaluation for MBI does not depend on the probe substrates used in the assay. In addition, we established an automated assay to distinguish quasi-irreversible and irreversible binding to CYP3A in which the quasi-irreversible inhibitors such as diltiazem, verapamil, and nicardipine were dissociated from CYP3A by the addition of potassium ferricyanide, whereas the irreversible inhibitors such as clozapine, delavirdine, and mibefradil were not. It provides useful information related to chemical structures likely to cause MBI. By using these MBI assays supported by an extensive database of marketed compounds, a systematic MBI evaluation paradigm was established and has been incorporated into our drug discovery process.

Key words: CYP inhibition, cytochrome P450, drug-drug interactions, drug-induced hepatotoxicity, high throughput screening, mechanism-based inhibition, MI complex, metabolite-inhibitor complex, reactive intermediate

This article has been cited by other articles:

				A. Ogasawara, I. Negishi, K. Kozakai, and T. Kume In Vivo Evaluation of Drug-Drug Interaction via Mechanism-Based Inhibition by Macrolide Antibiotics in Cynomolgus Monkeys Drug Metab. Dispos., November 1, 2009; 37(11): 2127 - 2136. [Abstract] [Full Text] [PDF]

				S. W. Grimm, H. J. Einolf, S. D. Hall, K. He, H.-K. Lim, K.-H. J. Ling, C. Lu, A. A. Nomeir, E. Seibert, K. W. Skordos, et al. The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America Drug Metab. Dispos., July 1, 2009; 37(7): 1355 - 1370. [Abstract] [Full Text] [PDF]

				P. H. Bui, A. Quesada, A. Handforth, and O. Hankinson The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil Drug Metab. Dispos., July 1, 2008; 36(7): 1291 - 1299. [Abstract] [Full Text] [PDF]